Delisting risk
Bone Biologics (BBLG)
Develops an investigational NELL-1 bone-graft candidate for lumbar spinal fusion.
$0.5600
Pre-market−0.01 (−2.27%)
At close$0.5730(+1.70%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Research & development | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | |
| General & administrative | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −2 | −1 | −1 | −1 | −1 | −2 | −1 | −1 | −1 | −1 | −1 | −1 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −2 | −2 | −1 | −1 | −1 | −2 | −1 | −1 | −1 | −1 | −1 | −1 |
| Net income from continuing operations | −2 | −2 | −1 | −1 | −1 | −2 | −1 | −1 | −1 | −1 | −1 | −1 |
| Net income | −2 | −2 | −1 | −1 | −1 | −2 | −1 | −1 | −1 | −1 | −1 | −1 |
| EPS, basic | −$4.90 | −$3.38 | −$1.31 | −$0.67 | −$2.37 | −$0.48 | −$0.32 | −$1.33 | −$0.37 | −$0.63 | −$0.43 | −$0.43 |
| EPS, diluted | −$4.90 | −$3.38 | −$1.31 | −$0.67 | −$2.37 | −$0.48 | −$0.32 | −$1.33 | −$0.37 | −$0.63 | −$0.43 | −$0.43 |
| Weighted average shares, basic | 0 | 0 | 1 | 1 | 2 | 3 | 3 | 1 | 2 | 1 | 2 | 2 |
| Weighted average shares, diluted | 0 | 0 | 1 | 1 | 2 | 3 | 3 | 1 | 2 | 1 | 2 | 2 |
| EBITDA | 0 | −1 | −1 | −1 | −1 | −2 | −1 | −1 | 0 | −1 | −1 | −1 |
| Depreciation & amortization | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| EBIT | −2 | −2 | −1 | −1 | −1 | −2 | −1 | −1 | −1 | −1 | −1 | −1 |